Back to Search
Start Over
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis
- Source :
- International Journal of Immunopathology and Pharmacology
- Publication Year :
- 2018
-
Abstract
- Actinic keratosis (AK) is a clinical condition characterized by keratinocytic dysplastic lesions of the epidermis, affecting individuals chronically exposed to sunlight. Topical therapies allow the treatment of a whole area of affected skin and currently include diclofenac sodium gel, 5-fluorouracil cream, 5-fluorouracil and acetylsalicylic acid solution, imiquimod cream, and ingenol mebutate gel. Due to the comparable efficacy of 3% diclofenac, ingenol mebutate, and 3.75% imiquimod in treating AK multiple lesions, a pharmacoeconomic evaluation of cost-effectiveness of the three treatments was needed. A cost-efficacy analysis comparing 3% diclofenac sodium with ingenol mebutate and 3.75% imiquimod was performed. In this analysis, efficacy data were combined with quality-of-life measurement derived from previous studies as well as the costs associated with the management of these lesions in Italy. Patients’ demographics and clinical characteristics were assumed to reflect those from the clinical studies considered.
- Subjects :
- medicine.medical_specialty
Ingenol Mebutate Gel
Diclofenac
Cost-Benefit Analysis
Drug Compounding
Immunology
Ingenol mebutate
Imiquimod
diclofenac gel
030207 dermatology & venereal diseases
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Adjuvants, Immunologic
medicine
actinic keratosis
Immunology and Allergy
Humans
Multicenter Studies as Topic
030212 general & internal medicine
Letter to the Editor
Randomized Controlled Trials as Topic
Pharmacology
pharmacoeconomy
Epidermis (botany)
business.industry
Actinic keratosis
Anti-Inflammatory Agents, Non-Steroidal
Decision Trees
Diclofenac Sodium
Cost efficacy
medicine.disease
Dermatology
Keratosis, Actinic
dermatology
Treatment Outcome
chemistry
Clinical Trials, Phase III as Topic
Aminoquinolines
Diterpenes
business
medicine.drug
Subjects
Details
- ISSN :
- 20587384
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- International journal of immunopathology and pharmacology
- Accession number :
- edsair.doi.dedup.....be322942ad8214fbec912904476f976a